Levi Garraway (Broad Institute via YouTube)
Roche goes 0-2 in the high-stakes race to get a TIGIT through PhIII and onto the market
Roche has racked up its second straight Phase III fail for its TIGIT tiragolumab, flagging a flop on the progression-free survival co-primary endpoint for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
